Dr. Vera Bittner
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of South Alabama College of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 136
Licensed in Alabama since 1984, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: University of South Alabama College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
AL license 11430 (first issued 1984; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 136
- Services billed
- 249
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 73 | 31 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 43 | 42 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 33 | 31 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 17 | 17 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Birmingham, AL | 133 |
| Repatha Sureclick (evolocumab) Other prescribers in Birmingham, AL | 72 |
| Spironolactone Other prescribers in Birmingham, AL | 71 |
| Potassium Chloride Other prescribers in Birmingham, AL | 70 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Birmingham, AL | 68 |
| Carvedilol Other prescribers in Birmingham, AL | 65 |
| Torsemide Other prescribers in Birmingham, AL | 62 |
| Amlodipine Besylate Other prescribers in Birmingham, AL | 58 |
| Furosemide Other prescribers in Birmingham, AL | 54 |
| Ezetimibe Other prescribers in Birmingham, AL | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $71,296 in research payments for these studies, mostly to the institutions running them.
- HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals Corporation - REDEFINE-HF Study #22438
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.